HUBEI PROVINCE, CHINA--(Marketwire - October 29, 2007) - Benda Pharmaceutical, Inc. (“Benda” or the “Company”) (OTCBB: BPMA), a China-based pharmaceutical company producing traditional Chinese and conventional medicines, as well as Gendicine®, the world’s first commercialized gene therapy medicine for the treatment of cancer, announced today that its subsidiary SiBiono has made major strides in developing an anti-AIDS gene therapy. This marks SiBiono’s and Benda’s anticipated entry into the $14 billion Chinese anti-AIDS drug market.
